Protalix Biotherapeutics Stock Performance
| PLX Stock | USD 2.38 0.03 1.28% |
On a scale of 0 to 100, Protalix Biotherapeutics holds a performance score of 15. The company holds a Beta of 0.37, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Protalix Biotherapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Protalix Biotherapeutics is expected to be smaller as well. Please check Protalix Biotherapeutics' potential upside, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Protalix Biotherapeutics' historical price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Protalix Biotherapeutics are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain essential indicators, Protalix Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.28 | Five Day Return (2.86) | Year To Date Return 20.81 | Ten Year Return (87.92) | All Time Return (99.72) |
Last Split Factor 1:10 | Dividend Date 2019-12-20 | Last Split Date 2019-12-20 |
1 | Protalix BioTherapeutics Issues 2025 Letter to Stockholders | 12/23/2024 |
2 | Acquisition by Rubin Eyal of 99010 shares of Protalix Biotherapeutics subject to Rule 16b-3 | 12/27/2024 |
3 | Protalix BioTherapeutics, Inc. Shares Sold by Jane Street Group LLC - MarketBeat | 01/16/2025 |
4 | Acquisition by Dror Bashan of 16129 shares of Protalix Biotherapeutics at 1.41 subject to Rule 16b-3 | 01/24/2025 |
5 | Protalix BioTherapeutics to Participate in the 2025 BIO CEO Investor Conference | 02/04/2025 |
6 | StockNews.com Downgrades Protalix BioTherapeutics to Buy - MarketBeat | 02/07/2025 |
| Begin Period Cash Flow | 17.1 M |
Protalix |
Protalix Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 172.00 in Protalix Biotherapeutics on November 28, 2024 and sell it today you would earn a total of 66.00 from holding Protalix Biotherapeutics or generate 38.37% return on investment over 90 days. Protalix Biotherapeutics is generating 0.6007% of daily returns assuming volatility of 3.1492% on return distribution over 90 days investment horizon. In other words, 28% of stocks are less volatile than Protalix, and above 89% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Protalix Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Protalix Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Protalix Biotherapeutics, and traders can use it to determine the average amount a Protalix Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1907
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PLX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.15 actual daily | 28 72% of assets are more volatile |
Expected Return
| 0.6 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.19 actual daily | 15 85% of assets perform better |
Based on monthly moving average Protalix Biotherapeutics is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Protalix Biotherapeutics by adding it to a well-diversified portfolio.
Protalix Biotherapeutics Fundamentals Growth
Protalix Stock prices reflect investors' perceptions of the future prospects and financial health of Protalix Biotherapeutics, and Protalix Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protalix Stock performance.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.0747 | ||||
| Profit Margin | (0.21) % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 151.31 M | ||||
| Shares Outstanding | 73.63 M | ||||
| Price To Earning | (1.23) X | ||||
| Price To Book | 5.33 X | ||||
| Price To Sales | 3.84 X | ||||
| Revenue | 65.49 M | ||||
| Gross Profit | 16.38 M | ||||
| EBITDA | 11.65 M | ||||
| Net Income | 8.31 M | ||||
| Cash And Equivalents | 17.11 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 26.28 M | ||||
| Current Ratio | 1.33 X | ||||
| Book Value Per Share | 0.44 X | ||||
| Cash Flow From Operations | (1.32 M) | ||||
| Earnings Per Share | (0.15) X | ||||
| Market Capitalization | 175.25 M | ||||
| Total Asset | 84.43 M | ||||
| Retained Earnings | (381.55 M) | ||||
| Working Capital | 24.4 M | ||||
| Current Asset | 59.65 M | ||||
| Current Liabilities | 10.33 M | ||||
About Protalix Biotherapeutics Performance
Evaluating Protalix Biotherapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Protalix Biotherapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Protalix Biotherapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 272.23 | 366.40 | |
| Return On Tangible Assets | 0.11 | 0.12 | |
| Return On Capital Employed | 0.31 | 0.32 | |
| Return On Assets | 0.11 | 0.12 | |
| Return On Equity | 0.22 | 0.21 |
Things to note about Protalix Biotherapeutics performance evaluation
Checking the ongoing alerts about Protalix Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protalix Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Protalix Biotherapeutics appears to be risky and price may revert if volatility continues | |
| Protalix Biotherapeutics has about 17.11 M in cash with (1.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Protalix Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: StockNews.com Downgrades Protalix BioTherapeutics to Buy - MarketBeat |
- Analyzing Protalix Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protalix Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Protalix Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Protalix Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protalix Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Protalix Biotherapeutics' stock. These opinions can provide insight into Protalix Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.